<DOC>
	<DOCNO>NCT00000626</DOCNO>
	<brief_summary>Primary : To assess toxicity chemotherapy ABVD ( doxorubicin / bleomycin / vinblastine / dacarbazine ) give filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) patient underlie HIV infection Hodgkin 's disease ; observe efficacy ABVD G-CSF reduce tumor burden HIV-infected patient Hodgkin 's disease . Secondary : To determine durability tumor response ABVD plus G-CSF 2-year study period ; observe incidence bacterial opportunistic infection HIV-infected patient Hodgkin 's disease receive regimen ; document quality life patient receive regimen . Addition granulocyte colony-stimulating factor may prevent neutropenia cause chemotherapy , allow timely administration chemotherapy improve response .</brief_summary>
	<brief_title>Phase II Study Filgrastim ( G-CSF ) Plus ABVD Treatment HIV-Associated Hodgkin 's Disease</brief_title>
	<detailed_description>Addition granulocyte colony-stimulating factor may prevent neutropenia cause chemotherapy , allow timely administration chemotherapy improve response . Study drug administer 28-day cycle twenty-seven HIV-infected patient Hodgkin 's disease . ABVD ( doxorubicin / bleomycin / vinblastine / dacarbazine ) administer day 1 15 cycle , G-CSF give day 2 14 16 28 cycle . All patient receive four cycle treatment restaged . Patients complete response ( CR ) follow initial four cycle receive two additional cycle ABVD / G-CSF . Patients partial response follow initial four cycle receive two additional cycle ABVD / G-CSF restaged ; achieve CR point receive two cycle , without CR discontinue study therapy . Patients disease progression follow initial four cycle therapy discontinue treatment study . Concomitant PCP prophylaxis administer .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis consist Bactrim , aerosolize pentamidine , dapsone . Recommended : Antiemetic therapy within 30 minute chemotherapy . Allowed : Antiretroviral medication two cycle chemotherapy , provide patient experience grade 3 neutropenia chemotherapy previous antiretroviral therapy . Acetaminophen and/or nonsteroidal antiinflammatory agent . Bone marrowsuppressive agent , ganciclovir , Fansidar , Bactrim , dapsone . Maintenance therapy chronic opportunistic infection . Concurrent Treatment : Allowed : Cranial irradiation ( 2400 rad ) patient CNS involvement . Patients must : Documented HIV infection diagnosis AIDS . Hodgkin 's disease . Consent parent guardian care directly supervise pediatric oncologist 18 year age . Prior Medication : Allowed : Maintenance therapy opportunistic infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Second primary cancer Kaposi 's sarcoma require systemic therapy , nonmelanomatous skin cancer , Bowen 's disease , carcinoma situ cervix . Acute , active bacterial opportunistic infection require ongoing therapy therapy initiate within past 2 week . Known hypersensitivity ( e.g. , anaphylactoid reaction , bronchospasm ) E. coliderived protein . Prior Medication : Excluded : Prior chemotherapy Hodgkin 's disease . Antiretroviral therapy within 2 week prior study entry . Prior Treatment : Excluded : Prior radiotherapy Hodgkin 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>ABVD protocol</keyword>
</DOC>